Europe says yes to biotechnology
European confidence and optimism in biotechnology is increasing, according to a survey conducted by the European Commission (EC), with particular support being seen in the area of regenerative medicines, including stem cell research and embryonic stem cell research.
European confidence and optimism in biotechnology is increasing, according to a survey conducted by the European Commission (EC), with particular support being seen in the area of regenerative medicines, including stem cell research and embryonic stem cell research.
According to the EC, biotechnology is a major driver in the health and wellbeing of European citizens, but many factors have affected its development including consumer safety concerns, strong environmental movements and little social acceptance. The EC’s Eurobarometer survey, however, showed that 80% of Europeans are in favor of, or unopposed to, biotechnology, although there is still a demand for more facts and communication.
Overall, there was great support for medical biotechnology, with 68% of respondents approving of stem cell research and 63% approving of embryonic stem cell research. Additionally, 58% of respondents approve of xenotransplantation, which is subject to moratoria in a number of countries. The support for medical biotechnology also reaches to non-therapeutic applications, with 56% of respondents approving of research aiming to enhance human performance. However, there was also a strong consensus that strict laws will be needed to alleviate concerns about ethical issues.
Biobanks were also well supported. Although only one in three respondents had heard about biobanks, nearly one in two said they would definitely or probably participate in them, with Scandinavian countries showing particularly enthusiasm.
“These findings are very encouraging,” Nathalie Moll, Secretary General at the European Association for Bioindustries (EuropaBio), said in a press statement. “They show that Europeans increasingly understand and appreciate the benefits that biotechnology brings... In particular, we are delighted by the overwhelming support for medical biotechnology and for the strong support shown for crop-based and non-food based biofuels.”
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Ensuring Quality from the Start: Raw Materials Testing Support
November 21st 2024Raw Materials are the foundation of every biopharma product. Our ultimate guide highlights how our testing support can help you establish purity, identity, and quality standards, ensuring a smooth manufacturing process and adherence to regulatory requirements.
Ensure the Safety of Allogeneic Therapies with Advanced qPCR Testing
November 21st 2024Elevate your viral screening with Eurofins BioPharma Product Testing’s qPCR- based assays. Our advanced testing goes beyond standard screenings to detect even dormant and hard-to-detect pathogens, ensuring comprehensive safety in every stage of the allogeneic therapy pipeline. Protect your products – and your patients- with industry-leading sensitivity and specificity.
